Antiparkinsonian drugs: Inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action

Joseph T. Coyle, Solomon H. Snyder

Research output: Contribution to journalArticlepeer-review

Abstract

A variety of antiparkinsonian drugs are potent, noncompetitive inhibitors of dopamine uptake into synaptosomes in homogenates of rat corpus striatum. Inhibition of dopamine uptake may potentiate the synaptic actions of dopamine in the striatum and could explain the antiparkinsonian effects of these drugs. This hypothesis accounts for several clinical features of Parkinson's disease and predicts compounds which may be new therapeutic agents.

Original languageEnglish (US)
Pages (from-to)899-901
Number of pages3
JournalScience
Volume166
Issue number3907
DOIs
StatePublished - Jan 1 1969

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Antiparkinsonian drugs: Inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action'. Together they form a unique fingerprint.

Cite this